Skip to main content
Elsevier

Ovarian Cancer

Disease, Diagnosis, and Treatment

  • 1st Edition - September 29, 2025
  • Latest edition
  • Editors: Bhupendra G. Prajapati, Mehul Chorawala, Seema Jadav
  • Language: English

By providing a comprehensive overview of current research findings, emerging therapies, and clinical practices, Ovarian Cancer: Disease, Diagnosis and Treatment is an invalu… Read more

Data Mining & ML

Unlock the cutting edge

Up to 20% on trusted resources. Build expertise with data mining, ML methods.

Explore now

Description

By providing a comprehensive overview of current research findings, emerging therapies, and clinical practices, Ovarian Cancer: Disease, Diagnosis and Treatment is an invaluable resource. It will not only enhance the understanding of ovarian cancer's complex biology among professionals but also guide them in applying this knowledge to improve patient outcomes The book delivers the key knowledge and information needs faced by the audience center around understanding the latest advances in the underlying pathogenesis and treatment of ovarian cancer. This encompasses a broad spectrum of requirements, from grasping the molecular and genetic factors driving ovarian cancer development to staying updated on the latest therapeutic strategies, including targeted therapies and immunotherapies. In 19 chapters Ovarian Cancer: Disease, Diagnosis and Treatment gives a timely and comprehensive coverage of advances in ovarian cancer therapy, particularly highlighting the development and utilization of Nanotheranostics technologies. This focus not only addresses a crucial and cutting-edge area of cancer treatment but also positions the book as a forward- thinking resource that delves into the potential of Nanotheranostics to revolutionize cancer diagnostics and therapy.

Ovarian Cancer: Disease, Diagnosis and Treatment targets a specialized audience within the medical and scientific community, focusing on obstetricians and gynecologists, oncologists, cancer researchers, and importantly, patients with ovarian cancer. This audience selection underscores the project's dual aim of advancing scientific knowledge and directly benefiting patient care in the realm of ovarian cancer, bridging the gap between research, clinical application, and patient advocacy.

Key features

  • Provides a comprehensive understanding of ovarian cancer
  • Gives insight in the diagnostics and treatment strategies of ovarian cancer
  • Describes the drugs used and novel formulation for targeting the treatment of ovarian cancer

Readership

Researchers working across the biosciences in the fields of oncology and gynecology

Table of contents

1. Understanding Ovarian Cancer

2. Epithelial Ovarian Cancer: The Most Common Subtype

3. Germ Cell Tumors: Ovarian Cancer in Young Women

4. Stromal Tumors: Exploring Rare Ovarian Cancer Types

5. Ovarian Oncosomes

6. Potential role of Microbiome in ovarian cancer

7. Early Detection Matters: Screening and Diagnostic Tools

8. Targeting Mitochondria for Treatment of Ovarian Cancer

9. Surgical Interventions: Reshaping the Battle against Ovarian Cancer

10. Natural Drugs for Ovarian Cancers

11. Novel Synthetic molecules for Ovarian Cancer

12. Chemotherapy: A Powerful Weapon in Ovarian Cancer Treatment

13. Radiation Therapy: Targeting Ovarian Cancer with Precision

14. Nanoparticles in treating Ovarian Cancer

15. Liposomes in treating Ovarian Cancer

16. Therapeutic Vaccines for Ovarian Cancer

17. The Genetic Puzzle: BRCA Mutations and Personalized Medicine

18. Life Beyond Treatment: Nurturing Survivorship

19. Monitoring for Recurrence: Follow-Up Care and Surveillance

Product details

  • Edition: 1
  • Latest edition
  • Published: October 15, 2025
  • Language: English

About the editors

BP

Bhupendra G. Prajapati

Dr. Bhupendra Gopalbhai Prajapati is Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India, and serves as Adjunct Professor in the Department of Industrial Pharmacy at Silpakorn University, Thailand. His academic, research, and industry expertise focuses on lipid‑based formulations, nano‑ and microparticulate drug delivery systems, and strategies to enhance drug bioavailability. Dr. Prajapati has received several academic and professional honors recognizing excellence in teaching and research. He has made substantial scholarly contributions through research and review publications, book chapters, and edited volumes in pharmaceutical sciences. Actively engaged in postgraduate and doctoral mentoring, he supports research training in advanced drug delivery and formulation science. Dr. Prajapati also serves in editorial and section‑editor roles for international scientific publications, contributing to the advancement and quality of pharmaceutical research dissemination.

Affiliations and expertise
Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Waghodia, Vadodara, Gujarat, India

MC

Mehul Chorawala

Dr. Mehul R. Chorawala works as an assistant professor at L. M. College of Pharmacy, Ahmedabad, Gujarat, India. He is an alumnus of the University of Iowa, IA, USA (Postdoctoral Fellow). He has decades of academic and industry experience mainly focusing on research. He published more dozens of international and national peer reviewed publications along with several books. He is an active member of American Heart Association (AHA) and Indian Pharmacological Society. His current research focus is on immune-inflammation, oxidative-nitrosative stress, medical oncology, metabolic disorders such as diabetes mellitus and its complications.

Affiliations and expertise
Assistant Professor, L. M. College of Pharmacy, Ahmedabad, Gujarat, India

SJ

Seema Jadav

Ms.Seema Jadav works as a Clinical Pharmacist in the UK. She received her Bachelor’s degree in Pharmacy from S.P. University in India and Masters in Public Health degree from Curtin University, Australia. She then moved to the U.K where she registered as a pharmacist. She currently works in a General Practitioner surgery alongside doctors, nurses and other health care professionals. She previously worked as a mental health pharmacist in hospitals for eight years for patients with critical disease. Whilst in this role she also acquired a Post Graduate Certificate in Psychiatric Therapeutics. She is now going to work towards securing a prescribing qualification to become a pharmacist prescriber with special interest in mental health, cancer, diabetes and hypertension.

Affiliations and expertise
Sanofi Pharmaceutical

View book on ScienceDirect

Read Ovarian Cancer on ScienceDirect